Simon Quick Advisors LLC Has $792,000 Stock Holdings in STERIS plc (NYSE:STE)

Simon Quick Advisors LLC grew its holdings in STERIS plc (NYSE:STEFree Report) by 79.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,853 shares of the medical equipment provider’s stock after buying an additional 1,707 shares during the quarter. Simon Quick Advisors LLC’s holdings in STERIS were worth $792,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new stake in STERIS in the third quarter worth about $25,000. Central Pacific Bank Trust Division acquired a new stake in STERIS in the third quarter worth about $28,000. Quarry LP acquired a new stake in STERIS in the third quarter worth about $67,000. Asset Dedication LLC increased its position in STERIS by 54.8% in the third quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock worth $71,000 after purchasing an additional 103 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in STERIS by 45.0% in the second quarter. EverSource Wealth Advisors LLC now owns 583 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 181 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.14% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Finally, Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $230.00 to $260.00 in a report on Thursday, October 24th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $262.50.

Check Out Our Latest Stock Report on STE

STERIS Trading Up 0.7 %

NYSE:STE opened at $218.54 on Thursday. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. The stock has a market capitalization of $21.57 billion, a PE ratio of 49.89 and a beta of 0.84. The business’s 50-day simple moving average is $211.68 and its 200-day simple moving average is $224.74.

STERIS (NYSE:STEGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business posted $2.03 EPS. STERIS’s revenue for the quarter was up 7.3% on a year-over-year basis. Sell-side analysts expect that STERIS plc will post 9.1 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.